Navigation Links
Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
Date:6/27/2012

WASHINGTON, June 27, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

"This is a tremendous step forward in addressing our most pressing health problem. Healthcare professionals now have a new option to help their patients affected by obesity manage this chronic condition. We are happy to see this latest evidence that the FDA is joining the effort to treat obesity seriously," said Dr. Patrick O'Neil, President of The Obesity Society.

Dr. O'Neil continued, "At the same time, it is important to understand that this medication will not work overnight or by itself. Lifestyle changes and support from qualified professionals are still necessary. This is an obesity medication, not a diet pill."

The OCC supports the FDA's continued dedication to excellence in ensuring the safety and effectiveness of new obesity treatments. With more than 93 million Americans affected by obesity, it is imperative to continue this proactive momentum and forward-thinking approach with all safe and effective therapies for the disease.

"We are very pleased with the FDA's decision. These are serious medications for a serious issue. In order for us to fight this epidemic, the right patients must receive the right treatment from a qualified physician in combination with a diet and exercise program," said Joe Nadglowski, Obesity Action Coalition (OAC) President and CEO.

About the Obesity Care Continuum (OCC):

With a combined membership of more than 125,000 healthcare professionals and patient advocates, the Obesity Care Continuum (OCC) is dedicated to promoting access to, and coverage of, the continuum of care surrounding the treatment of overweight and obesity. The OCC also challenges weight bias and stigma oriented policies – whenever and wherever they occur. The OCC is a coalition of the Obesity Action Coalition (OAC), the Obesity Society (TOS), and the American Society for Metabolic and Bariatric Surgery (ASMBS).


'/>"/>
SOURCE Obesity Care Continuum
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
2. LTCLINK-Tank Competition Announced To Introduce Your Emerging Product to the Aging Care Continuum
3. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
6. CHPA Applauds Alabamas Adoption Of HB 363
7. CHPA Applauds Alabama Senates Passage of Anti-Meth Bill
8. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
9. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
10. ERT Announces Stockholder Approval of Merger
11. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... LONDON , Feb. 27, 2017 This ... understand Teva and its partnering interests and activities since ... Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:2/28/2017)... 2017 Research and Markets has announced ... 2014-2025" report to their offering. ... The global digestive enzyme ... 2025. Growing consumer awareness regarding the severity of digestive disorders ... stimulate industry growth over the forecast period. The increasing incidence ...
(Date:2/28/2017)... ... Research and Markets has announced the addition of the "Orthobiologics ... The global orthobiologics market is expected to reach USD 10.2 ... predominantly driven by the increasing orthopedic disease and musculoskeletal disease burden ... of orthobiologics are presumed to accelerate the market demand over the ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... Roxanna Cross will host ... the 11th Annual RISE Nashville Summit. RISE Nashville is the healthcare industry’s premier ... strategies. , The discussion will include best practices for accurate identification and capture ...
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata ... Spiritual Awakening, is happy to announce her “Spring Rejuvenation in Sedona” personally ... individual customized retreats offer the winter-weary soul an excellent opportunity to come out ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... San Francisco, CA (PRWEB) , ... February 27, ... ... Area center for hair transplantation therapy, is proud to announce a new informational ... popular hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
Breaking Medicine News(10 mins):